Rutgers University-New Brunswick has spun out Infinity Biologix with backing from Viking Global Investors to manage the distribution of a saliva-based coronavirus test.
Infinity Biologix, a US-based coronavirus saliva test developer spun out of Rutgers University-New Brunswick, has launched with an initial $44.4m from investors including hedge fund Viking Global Investors, New Jersey Biz reported on Wednesday.
Spun out from the university’s RUCDR Infinite Biologics lab, Infinity Biologix has received emergency-use authorisation in the US for a coronavirus saliva test that can be performed from a patient’s home.
The aim is to enable more comprehensive testing than existing nose or throat…
